Literature DB >> 18521214

Amplification of the MYC Gene in Osteosarcoma Secondary to Paget's Disease of Bone.

T Ueda1, J H Healey, A G Huvos, M Ladanyi.   

Abstract

Purpose. In a previous series of 25 human osteosarcoma samples studied for MYC gene amplification, we found amplification in two cases (8%), including one arising in association with Paget's disease (pagetic osteosarcoma). Based on this observation, we further investigated the prevalence of MYC gene amplification in pagetic osteosarcomas.Methods. MYC gene amplification was assessed by Southern blot analysis using frozen tissue samples in five cases of pagetic osteosarcoma and 53 cases of primary (non-pagetic) osteosarcoma. Amplification was considered present if the MYC copy number was six or greater.Results. Three out of five patients (60%) with pagetic osteosarcoma showed MYC gene amplification, whereas it was present in only 5/53 patients (9.4%) with primary osteosarcoma. The incidence of MYC amplification in pagetic osteosarcoma was thus significantly higher than that in primary osteosarcoma (p = 0.016).Discussion. The finding that MYC gene amplification may be more common in pagetic than primary osteosarcoma warrants further study and suggests pathogenetic differences between primary osteosarcomas and those arising in the setting of Paget's disease. Three of the four pagetic osteosarcomas from the present study were previously shown to be immunoreactive for p53, suggesting that p53 mutation may also be a frequent genetic lesion in these tumors.

Entities:  

Year:  1997        PMID: 18521214      PMCID: PMC2395365          DOI: 10.1080/13577149778209

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  20 in total

1.  Comparable oncogene and tumor suppressor gene alterations in rat and human osteosarcomas.

Authors:  R J Isfort; D B Cody; G Lovell; C J Doersen
Journal:  Prog Clin Biol Res       Date:  1992

2.  Tumorigenicity of SEWA murine cells correlates with degree of c-myc amplification.

Authors:  T Martinsson; F Ståhl; P Pollwein; A Wenzel; A Levan; M Schwab; G Levan
Journal:  Oncogene       Date:  1988-10       Impact factor: 9.867

3.  Low level amplification of c-sis and c-myc in a spontaneous osteosarcoma model.

Authors:  D T Kochevar; J Kochevar; L Garrett
Journal:  Cancer Lett       Date:  1990-09       Impact factor: 8.679

4.  Cdc25 cell-cycle phosphatase as a target of c-myc.

Authors:  K Galaktionov; X Chen; D Beach
Journal:  Nature       Date:  1996-08-08       Impact factor: 49.962

5.  Amplification and rearrangement of c-myc in radiation-induced murine osteosarcomas.

Authors:  S A Sturm; P G Strauss; S Adolph; H Hameister; V Erfle
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

Review 6.  Radiation and pagetic osteogenic sarcomas.

Authors:  J H Healey; D Buss
Journal:  Clin Orthop Relat Res       Date:  1991-09       Impact factor: 4.176

Review 7.  Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer.

Authors:  M Schwab; L C Amler
Journal:  Genes Chromosomes Cancer       Date:  1990-01       Impact factor: 5.006

8.  Two distinct cell lines derived from a human osteosarcoma.

Authors:  A Kawai; T Ozaki; S Ikeda; T Oda; M Miyazaki; J Sato; K Taketa; H Inoue
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

Review 9.  c-erbB-2 oncogene as a prognostic marker in breast cancer.

Authors:  T J Perren
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

10.  Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma.

Authors:  S Ikeda; H Sumii; K Akiyama; S Watanabe; S Ito; H Inoue; H Takechi; G Tanabe; T Oda
Journal:  Jpn J Cancer Res       Date:  1989-01
View more
  13 in total

1.  Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma.

Authors:  Venugopal Thayanithy; Aaron L Sarver; Reena V Kartha; Lihua Li; Andrea Y Angstadt; Matthew Breen; Clifford J Steer; Jaime F Modiano; Subbaya Subramanian
Journal:  Bone       Date:  2011-10-18       Impact factor: 4.398

2.  The role of surgery and adjuvants to survival in Pagetic osteosarcoma.

Authors:  Pietro Ruggieri; Teresa Calabrò; Maurizio Montalti; Mario Mercuri
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

Review 3.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

Review 4.  New therapeutic targets in soft tissue sarcoma.

Authors:  Elizabeth G Demicco; Robert G Maki; Dina C Lev; Alexander J Lazar
Journal:  Adv Anat Pathol       Date:  2012-05       Impact factor: 3.875

5.  BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.

Authors:  Emma K Baker; Scott Taylor; Ankita Gupte; Phillip P Sharp; Mannu Walia; Nicole C Walsh; Andrew Cw Zannettino; Alistair M Chalk; Christopher J Burns; Carl R Walkley
Journal:  Sci Rep       Date:  2015-05-06       Impact factor: 4.379

6.  How microRNA and transcription factor co-regulatory networks affect osteosarcoma cell proliferation.

Authors:  Kathrin Poos; Jan Smida; Michaela Nathrath; Doris Maugg; Daniel Baumhoer; Eberhard Korsching
Journal:  PLoS Comput Biol       Date:  2013-08-29       Impact factor: 4.475

7.  The DNA helicase recql4 is required for normal osteoblast expansion and osteosarcoma formation.

Authors:  Alvin J M Ng; Mannu K Walia; Monique F Smeets; Anthony J Mutsaers; Natalie A Sims; Louise E Purton; Nicole C Walsh; T John Martin; Carl R Walkley
Journal:  PLoS Genet       Date:  2015-04-10       Impact factor: 5.917

8.  Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma.

Authors:  Lauren J Mills; Milcah C Scott; Pankti Shah; Anne R Cunanan; Archana Deshpande; Benjamin Auch; Bridget Curtin; Kenneth B Beckman; Logan G Spector; Aaron L Sarver; Subbaya Subramanian; Todd A Richmond; Jaime F Modiano
Journal:  Bone       Date:  2020-10-27       Impact factor: 4.398

9.  Genetically engineered mouse models and human osteosarcoma.

Authors:  Alvin Jm Ng; Anthony J Mutsaers; Emma K Baker; Carl R Walkley
Journal:  Clin Sarcoma Res       Date:  2012-10-04

Review 10.  Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.

Authors:  Ander Abarrategi; Juan Tornin; Lucia Martinez-Cruzado; Ashley Hamilton; Enrique Martinez-Campos; Juan P Rodrigo; M Victoria González; Nicola Baldini; Javier Garcia-Castro; Rene Rodriguez
Journal:  Stem Cells Int       Date:  2016-06-05       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.